These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9111610)

  • 21. The current role and limitations of surrogate endpoints in advanced prostate cancer.
    Gomella LG; Oliver Sartor A
    Urol Oncol; 2014 Jan; 32(1):28.e1-9. PubMed ID: 23433893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.
    Collette L; Burzykowski T; Schröder FH
    Eur J Cancer; 2006 Jul; 42(10):1344-50. PubMed ID: 16730974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of adaptive designs for phase II cancer trials.
    López MF; Dupuy JF; Gonzalez CV
    Contemp Clin Trials; 2012 Jan; 33(1):223-7. PubMed ID: 22001360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials.
    Tangen CM; Goodman PJ; Crowley JJ; Thompson IM
    J Urol; 2004 Feb; 171(2 Pt 2):S64-7. PubMed ID: 14713757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
    Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternate endpoints for screening phase II studies.
    Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
    Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endpoints in prostate cancer clinical trials.
    Sartor O
    Urology; 2002 Sep; 60(3 Suppl 1):101-7; discussion 107-8. PubMed ID: 12231062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practice and progress in kidney cancer: methodology for novel drug development.
    Rini BI; Weinberg V; Small EJ
    J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
    Reese AC; Landis P; Han M; Epstein JI; Carter HB
    J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal two-stage randomized multinomial designs for Phase II oncology trials.
    Sun LZ; Chen C; Patel K
    J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
    Vickers AJ; Ballen V; Scher HI
    Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.
    Loeb S; Bruinsma SM; Nicholson J; Briganti A; Pickles T; Kakehi Y; Carlsson SV; Roobol MJ
    Eur Urol; 2015 Apr; 67(4):619-26. PubMed ID: 25457014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.
    Cabarrou B; Mourey L; Dalenc F; Balardy L; Kanoun D; Roché H; Boher JM; Rougé-Bugat ME; Filleron T
    Breast Cancer Res Treat; 2017 Aug; 164(3):505-513. PubMed ID: 28488143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates for advanced prostate cancer.
    Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.